Neuland Laboratories Ltd

Production Started

Neuland Laboratories Production Started

Neuland commissioned its first commercial peptide manufacturing module with 7,000L reactor capacity. Module two expansion is underway to meet rising customer demand for peptide APIs.

peptide manufacturing reactor capacity

7000 L

Capacity Expansion

Neuland Laboratories Capacity Expansion: ₹126 Cr Investment

Neuland Laboratories' board approved ₹126 Crore capex to acquire 134 acres of land in Andhra Pradesh for future expansion. The company holds ROFR on additional land.

Value

₹126.0 Cr

land acquisition

134.0 acres

Earnings Call

Neuland Laboratories Earnings Call Transcript: Key Takeaways

Q1FY27 was broadly in line with expectations, showing strong YoY revenue and profit growth. Management remains confident in achieving a 20% growth rate despite inherent quarterly volatility in the CMS business.

Call

Guides 20% growth

Earnings Call

Neuland Laboratories Investor Presentation: Key Takeaways

Neuland reported Q1FY27 total income of ₹650.1 Cr (116.3% YoY growth) with an EBITDA margin of 35.5%. Growth is driven by the CMS business and commercial molecules.

Financial Results

Neuland Laboratories Q1 FY27 Results: Net Profit ₹147.7 Cr, Up 962.6% YoY

Neuland Laboratories Ltd reported revenue from operations of ₹641.6 Cr (+119.1% YoY) and net profit of ₹147.7 Cr (+962.6% YoY) for Q1 FY27.

Key figure

Net profit ₹147.7 Cr · +962.6% YoY